Free Trial

Lexicon Pharmaceuticals Q2 2023 Earnings Report

Lexicon Pharmaceuticals logo
$0.46 +0.00 (+0.72%)
As of 04:00 PM Eastern

Lexicon Pharmaceuticals EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Lexicon Pharmaceuticals Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.30 million
Beat/Miss
Beat by +$20.00 thousand
YoY Revenue Growth
N/A

Lexicon Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Lexicon Pharmaceuticals Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Lexicon stock soars on Novo Nordisk licensing deal
Lexicon announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon announces exclusive license agreement with Novo Nordisk for LX9851
See More Lexicon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexicon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexicon Pharmaceuticals and other key companies, straight to your email.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (NASDAQ:LXRX), a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

View Lexicon Pharmaceuticals Profile

More Earnings Resources from MarketBeat